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POPULAR SCIENCE SUMMARY OF THE THESIS 
 
Lymphoid neoplasms are cancers stemming from the lymphocyte, a type of white blood cell, 
and include the different subtypes of lymphomas, including chronic lymphocytic leukemia as 
well as multiple myeloma. They arise at different stages in the development of the 
lymphocyte with different genetic markers and give rise to varying disease scenarios and 
treatment needs. 
Towards the end of the last century, the incidence (the number of new cases per 100 000 
persons and year) increased rapidly, for mostly unknown reasons. During the same period, 
many new medications were increasingly used in Europe and North America. Among the 
most common are aspirin (used as protection against heart attacks and stroke) and statins 
(used to lower blood cholesterol). Both of these medications have been described to be able 
to interfere with cancer development. 
In study I and II we used Swedish health-care registers to investigate if statin use improved 
survival in myeloma (study I) and lymphoma (study II). We found that statins seemed to 
improve survival in myeloma, but there did not seem to be a protective effect in subtypes of 
lymphoma. It is not possible to draw firm conclusions from our study about whether statin 
use improves survival in myeloma patients, as other analytical reasons could have contributed 
as well. However, we believe the result should be followed up in further studies. 
In study III we used data from patients in a large American cohort, the Nurses’ Health study. 
We made detailed calculations of their aspirin use, and found that users of many aspirin 
tablets/week (5 or more on average) had an increased risk of the follicular lymphoma 
subtype. We could not find evidence that persons using aspirin for longer periods of time had 
a higher risk of developing lymphoma. 
In study IV, we investigated primary central nervous system lymphoma (PCNSL), an 
uncommon lymphoma subtype that arises within the brain or spinal cord. PCNSL 
traditionally has a dismal prognosis, but many new treatments have been introduced lately. 
We calculated the incidence (number of new PCNSL diagnoses /100,000 persons and year) in 
Sweden, and found that the incidence is increasing among persons 70 years and older, but 
that other brain tumors are increasing in this age group as well. We therefore suspect that the 
increase, at least in part, is caused by more diagnostic procedures and reporting in this age 
group. We also investigated survival in PCNSL, and we did not find any improvement in 





Lymphoid neoplasms are malignancies arising from the lymphocyte, and include lymphoma 
subtypes, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). It is a 
heterogenous group of diseases, with different molecular pathogenesis, clinical 
characteristics, treatments and outcome. There is increasing understanding that risk factors 
may differ between the subtypes. 
The incidence of the non-Hodgkin subtypes of lymphoma (NHL) increased rapidly for 
several decades during the end of the 20th century, for mostly unknown reasons. Concurrently 
the use of many prophylactic medications such as statins and aspirin became common in 
Europe and North America. Anti-carcinogenic properties have been described in both these 
medications, but for statins there has also been concern about a potential conflicting effect of 
statins in lymphoma treatments that include the widely used monoclonal antibody rituximab. 
In study I and II we investigated the association between statin use and disease-specific 
mortality in lymphoid neoplasms. We assessed statin exposure in 6-month periods before and 
after diagnosis of a lymphoid neoplasm in cohort studies, and at any time during follow-up in 
nested case-control studies. We assessed the dose-response relationship by categories of 
intensity of statin use (according to American College of Cardiology/American Heart 
Association guidelines as low, moderate and high intensity) and duration. In study I, we 
found that among patients with MM, statin use was associated with improved myeloma-
specific mortality in all time-windows assessed. There was however no significant trend for 
dose intensity or duration. In study II, we found no association between statin use and 
lymphoma-specific survival in NHL overall or in CLL and other subtypes. We found 
improved lymphoma-specific survival in Burkitt lymphoma and in CLL patients that used 
statins for >2 years, but these findings could also be due to chance. We found no evidence of 
reduced efficacy of rituximab treatment for patients with statin use, which is reassuring. 
In study III we used the American cohort the Nurses’ Health Study to assess detailed 
information on aspirin use over 25+ years and risk of NHL and its subtypes. We investigated 
both cumulative average quantity and duration of aspirin use. We found no association 
between aspirin use and risk of NHL overall, but there was an increased risk of follicular 
lymphoma for users of large quantities of aspirin (5+ tablets/week), as well as a significant 
trend across increasing categories of quantity. 
In study IV we investigated the incidence of primary central nervous system lymphoma 
(PCNSL), a rare NHL subtype located in the CNS. PCNSL has traditionally had a dismal 
prognosis, but many new treatment schemes have been introduced lately. We found an 
increasing incidence primarily in the elderly (70+) that was consistent with an increasing 
trend of brain tumors of all types in the same age group, suggesting that this can, at least in 
part, be due to increased diagnostic procedures and reporting. We did not find any 
improvement in survival during the study period, indicating that the new treatments have not 
yet improved the prognosis in a population-based setting.   
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Lymphoid neoplasms are cancers stemming from the lymphatic white blood cell (Fig 1.1). 
The traditional division in myelomas and lymphomas, the latter further divided in Hodgkin 
and non-Hodgkin lymphomas (NHL) has gradually developed, mainly based on 
histopathology, molecular genetics and clinical course. Due to new insights in the genetic 
alterations in these malignant cells, the NHL entity was finally replaced entirely in the WHO 
2008 classification, and substituted by a division in mature B- and T-/natural killer (NK)-cell 
lymphoid neoplasms.1 Here multiple myeloma (MM) and chronic lymphocytic leukemia 
(CLL) are included in the “mature B-cell lymphoid neoplasms” group, which was 
additionally modified in the latest 2016 edition.2,3 The term NHL is, however, still widely 
used in the current literature and cancer statistics of today, and will also be referred to in this 
thesis, whereas Hodgkin lymphoma will not be addressed further. Primary central nervous 
system lymphoma (PCNSL), a lymphoma arising within the brain or spinal cord, is not 
recognized as a separate entity by the WHO, given that it is not possible to distinguish 
morphologically from the common NHL subtype diffuse large B-cell lymphoma (DLBCL) 
that is located in other parts of the body.1  
 
 
Fig 1.1 The principles of hematopoiesis. Illustration by Hanna Närding 
The clinical manifestations of lymphoma span from indolent disease to highly proliferative 
disease, requiring immediate treatment. The prognosis varies considerably between subtypes 
of lymphoma, with a reported relative 5-year survival for NHL overall at around 73%, 
translating to approximately 600 deaths yearly in Sweden4 and 20,000 deaths yearly in the 
US.5 The age-adjusted incidence rate of NHL in the US is approximately 19.6 per 100,000 
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person-years (cases diagnosed from 2013–2017) with an estimated 77,240 new cases in 2020, 
accounting for 4.3% of all new cancers in the US in 2020.5 The corresponding incidence rate 
of CLL is 5.0 per 100,000 person-years with an estimated new 21,040 cases in the US in 
2020.6 The incidence rates in Sweden are similar, and 1,907 incident diagnoses of NHL and 
670 of CLL were reported in 2017.7 In the uncommon subtype primary central nervous 
system lymphoma (PCNSL), only approximately 30 new cases are diagnosed yearly in 
Sweden,8 accounting for approximately 1% of NHLs and about 3% of all primary brain 
tumors9.  
For MM, many new treatments have been introduced during the last decade, and survival has 
improved considerably.10 For the period 2010-2016 the relative 5-year survival was 54% in 
the US11 and the age-adjusted incidence rate 7.0 per 100,000 person-years, or an estimated 
32,270 new cases in 2020.11 The incidence rate in Sweden is similar, with 849 MM diagnoses 
reported in 2017.7 A Swedish study has shown that 2.7% of MM patients have a previous 
diagnosis of a monoclonal gammopathy of undetermined significance (MGUS), the precursor 
state of MM, in which the monoclonal (M)-protein concentration typical for MM has been 
diagnosed in the blood but without the patient fulfilling other criteria of MM.12 These patients 
are followed with regular testing of their M-protein in order to identify a potential progression 
to MM, and to provide early treatment and improve survival.  
Whereas the incidence of MM has remained relatively stable in recent decades, NHL 
incidence in Europe and North America was increasing steeply between 1970 and 2000, 
when it plateaued, and since 2008 has been slightly decreasing.5 Little is still known about the 
reasons for these changes in either direction (Fig 1.2).  
 
Fig 1.2 Age-adjusted NHL incidence and death rates per 100,000 person-years in the US 
Reprint from the Surveillance, Epidemiology, and End Results (SEER) Program 
(www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, 
Nov 2020 Sub (1975-2018). 
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Among the NHL subtypes, a special interest has been a potential increase in the uncommon 
subtype of primary central nervous system lymphoma (PCNSL), a type of diffuse large B-cell 
lymphoma (DLBCL) that arises within the CNS.13,14 This subtype has traditionally had a 
dismal prognosis, but new treatments have been introduced in the last decades, raising the 
hope of improved outcomes for patients with this subtype.15 
During the same period, use of certain medications has increased in Europe and North 
America, among these, the common drugs aspirin and statins.16,17 Interesting potential 
interactions of these medications in carcinogenesis and cancer proliferation have been 
hypothesized in several other cancer forms, but little is known about these medications in the 
etiology and prognosis of lymphoid neoplasms. A potential protective effect of aspirin in risk 
of lymphoma, equivalent to what has been shown in colorectal cancer, would be highly 
valuable. At the same time, a possible interaction between concomitant medications such as 
statins with other antitumoral treatments, thus inhibiting their effect, would also have large 
implications. 
In this thesis we aimed to analyze the role of common medications in the etiology and 
prognosis of lymphoid neoplasms, and investigate the incidence and prognosis of PCNSL. 
Specifically, we have used the Swedish population-based registers to investigate if statin use 
affects the prognosis of myeloma or subtypes of lymphoma including CLL, and we have used 
American prospective cohort data to explore if regular use of aspirin affects the risk of 
lymphoma. We have also used the Swedish registers to calculate recent incidence rates of 




2 LITERATURE REVIEW 
2.1 ETIOLOGY AND RISK FACTORS 
Lymphomas of B-cell origin constitute about 95% of all lymphomas; the rest are T-cell 
malignancies. The latest WHO classification includes 17 different main subtypes among the 
mature B-cell neoplasms, among them CLL and MM (Table 2.1).3 The different B-cell 
subtypes arise at different stages in the normal development of the B cell (Fig 2.1) and have 
different behaviors in terms of pathogenesis, clinical presentation and treatment. 
Table 2.1 Human mature B-cell neoplasms according to the WHO classification 
Lymphoma subtype Frequency among lymphomas (%)* 
B-cell chronic lymphocytic leukemia (B-CLL) 7 
Mantle-cell lymphoma 5 
B-cell prolymphocytic leukemia <1 
Follicular lymphoma 20 
Hairy-cell leukemia <1 
Mucosa associated lymphoid tissue (MALT) lymphoma 7 
Nodal marginal-zone lymphoma 2 
Splenic marginal-zone lymphoma 1 
Burkitt’s lymphoma 2 
Diffuse large B-cell lymphoma 30-40 
Primary mediastinal B-cell lymphoma 2 
Post-transplant lymphoma <1 
Primary effusion lymphoma <0.5 
Lymphoplasmacytic lymphoma 1 
Multiple myeloma 10 
Classical Hodgkin’s lymphoma 10 
Lymphocyte-predominant Hodgkin’s lymphoma 0.5 
*These numbers refer to the frequencies in Europe and North America. 
 
Known risk factors for lymphoma include immune suppression, such as after organ 
transplantation,18 and certain infections, such as Epstein-Barr virus (EBV)19 and Human 
Immunodeficiency virus (HIV),20 or infection with helicobacter pylori in gastric mucosa 
associated lymphoid tissue lymphoma (MALT)21 and chlamydia psittaci in ocular adnexal 
marginal zone lymphoma.22 Constitutive inflammatory activation is also believed to increase 
the risk of lymphoma, as exemplified by an increased lymphoma incidence in patients with 
inflammatory diseases such as Sjögren’s syndrome, rheumatoid arthritis (RA) and 
inflammatory bowel disease.23,24  
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Prognostic risk factors include both clinical and tumor molecular characteristics. The tumor 
microenvironment and more broadly the host background in terms of heredity, tumor 
genetics, and co-morbidity may also be additional critical factors in lymphoma progression. 
Concurrent medications used for other diseases may thus play a role in NHL progression as 
well. There is growing appreciation that, given the large morphological and molecular 
differences between the subtypes, risk factors may also differ between them, underscoring the 
importance of investigating different subtypes separately.25  
 
Fig 2.1 Cellular origin of human B-cell lymphomas. Reprint from Ralph Kuppers: 
Mechanisms of B-cell lymphoma pathogenesis, Nature Reviews cancer, 2005 26 
2.2 STATINS 
Statins are among the most frequently prescribed classes of drugs in Europe and North 
America,16,17 primarily indicated in the treatment of hyperlipidemia. An estimated one in 10 
adults and one in four individuals ≥ 60 years old are currently on statin therapy in the US.27 
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase, the rate-
limiting enzyme of the mevalonate pathway, thereby reducing cholesterol synthesis (Fig 2.2). 
The impact of statins on cholesterol and isoprenoid synthesis may have anticancer effects 
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through several mechanisms important for tumor survival.28 Consistent with this hypothesis, 
many epidemiological studies support an anti-cancer effect in several solid cancers.29-31 
 
Fig 2.2 Statin and nitrogen-containing bisphosphonate mechanism of action on the 
mevalonate pathway. Reprint from Sanfilippo: Statins are associated with reduced mortality 
in multiple myeloma, Journal of Clinical Oncology, 2016.32 
2.2.1 Statins and prognosis in lymphoid neoplasms 
Statins have been shown to inhibit lymphoma cell proliferation in vitro.33 There has been 
concern, however, that statins may also inhibit the effect of the monoclonal antibody 
rituximab, which is widely used in lymphoma treatment, given that in vitro data have shown 
inhibited binding of rituximab to its effector receptor, CD20, in the presence of statins.34 This 
negative effect has not been confirmed in vivo, but most studies have included few or highly 
selected patients.35-38 Most authors suggest that associations with statins are likely to be 
different in different subtypes of lymphoma, and possibly also context-dependent, e.g. with 
associations depending on the treatment combination. A summary of the results of previously 
published studies assessing statin use and prognosis of lymphoma overall, or subtypes, can be 
found in Table 2.2. 
In patients with MM, several small studies (n=9 to 146) in the relapsed and refractory setting 
have suggested that statins are well tolerated in combination with other therapies,39-41 but only 
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one large study has been published, in American veterans (n=4,957), which reported 
improved survival for statin users.32 
There are several possible pathways suggested for statins to interfere in the progression of 
lymphoid neoplasms, such as its ability to down-regulate NF-κB signaling, which is a 
therapeutic target of interest in MM.42-44 Furthermore, statins are suggested to be able to 
modulate the BCL2 family proteins which promote cell survival and chemoresistance in 
multiple cancer types including lymphoma.45 Moreover, in vitro studies have shown that 
statins affect the same anti-osteoclast mechanisms as bisphosphonates,46 a medication 
included as prophylaxis and treatment of osteolytic lesions in MM patients.
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Table 2.2 Studies on statin and NHL survival 




Am J Hematol 
201638 
Statin use is safe and does not impact 
prognosis in patients with de novo 
follicular lymphoma treated with 
immunochemotherapy: An exploratory 
analysis of the PRIMA cohort study 
The PRIMA cohort, patients with de 





statin users at 
diagnosis) 
FL Comparable treatment response 
and survival in terms of all 
investigated outcome measures, 





Statin-independent prognosis of patients 
with diffuse large B-cell lymphoma 
receiving rituximab plus CHOP therapy 
Newly diagnosed DLBCL patients with 
R-CHOP treatment at the Cancer 
Institute Hospital and Okayama 
University Hospital, Japan 
256 patients, 
including 35 statin 
users 





Statin use and prognosis in patients with 
DLBCL and FL in the rituximab era 
Consecutive patients from the Mayo 
Clinic Rochester and the University of 
Iowa 
228 DLBCL + 293 FL 
(21% of DLBCL and 
19% of FL patients 
were statin users) 
DLBCL + FL For DLBCL no association with 
ORR, EFS, OS 
For FL, improved EFS for statin 
users at baseline (HR = 0.45, 95% 
CI: 0.26, 0.77), including both 
rituximab-treated (HR = 0.38, 95% 
CI: 0.14, 1.07) and watch and wait 





Effect of concomitant statin, metformin 
or aspirin on rituximab treatment for 
DLBCL 
 
DLBCL receiving rituximab-based 
chemoimmunotherapy at the National 
Cancer Centre, Singapore 
213 (47 (22.1%) were 
statin users) 
DLBCL Response rate and EFS similar, the 






Statin use has negative clinical impact 
on non-germinal center in patients with 
diffuse large B cell lymphoma in 
rituximab era 
De novo DLBCL receiving R-CHOP 
therapy from five medical centers in 
Korea 
409 (146 patients 
(35.7%) statin users 




Statin had significant negative 
impact on survival of the non-GC 
type (3-year PFS, multivariate adj 
HR = 1.55, 95% CI: 1.06, 2.28, p = 
0.024) OS (HR = 1.53, 95% CI: 





Concomitant statin use does not impair 
the clinical outcome of patients with 
diffuse large B cell lymphoma treated 
with rituximab-CHOP 
DLBCL with first line R-CHOP treatment 
at University Hospital Zürich or Triemli 
City Hospital Zürich; Switzerland 
145 patients (21 
(15%) received statins 
throughout therapy) 
DLBCL No adverse impact on response to 
chemotherapy, EFS, and OS 
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Smyth L.  
Br J Haematol 
202050 
Statin and  cyclooxygenase-2 inhibitors 
improve survival in newly diagnosed 
diffuse large B-cell lymphoma: a large 
population-based study of 4913 subjects 
Patients >66 years diagnosed with 
DLBCL or transformed FL treated with 
rituximab-containing regimen as first line 
therapy with curative intent, Population-
based study Ontario, Canada 






Statin exposure for 30 days (HR = 
0.97, 95% CI: 0.96, 0.98), 
Exposure 180 days (HR = 0.84, 
95%CI: 0.80, 0.89), Exposure 365 






Statin and non-steroidal anti-
inflammatory drug use in relation to 
clinical outcome among patients with 
Rai stage 0 chronic lymphocytic 
leukemia 
Newly diagnosed CLL with Rai stage 0 686 patients (136 
(20%) statin users 





CLL Rai 0 No difference in time to treatment. 
No difference in time to salvage 
treatment for patients starting first-
line rituximab-containing treatment 
Mozessohn L.  
J Natl Cancer 
201752 
The association of dyslipidemia with 
chronic lymphocytic leukemia: a 
population-based study 
Population-based case-control study in 
Ontario, Canada, using administrative 
databases 
2,124 persons with 
CLL  
CLL Statins (modeled separately) 
(adjusted HR = 0.53, 95% CI: 0.46, 





Statin use and need for therapy in 
chronic lymphocytic leukemia 
CLL patients at diagnosis or at start of 
first treatment at the Duke University 
and Durham VA Medical Centers 
254 (65 (26%) on 
statins at time of 
diagnosis) 





A link between hypercholesterolemia 
and chronic lymphocytic leukemia 
CLL patients at the specialized CLL 
clinic at Sunnybrook, Canada 
231 (107 (46.3%) 
used statins at the 
start of the study) 
CLL Excluding patients with del 17p, 
TFT was prolonged for statin users 
(57.5 (IQR = 32, 8) vs 36 (IQR = 
11, 1) months, p<0.02). 
Chae, YK. 
Blood 201455 
Statin and aspirin use is associated with 
improved outcome of FCR therapy in 
relapsed/refractory chronic lymphocytic 
leukemia 
Relapsed/refractory CLL treated with 
salvage FCR 
280 patients (58 
patients received 
statins, aspirin, or 
both, 17 (6%) statins 
only) 
CLL Users of statins and aspirin had 
improved PFS (HR = 0.34, 95% CI: 
0.18, 0.65), OS (HR = 0.40, 95% 
CI: 0.21, 0.79) Not significant for 
statin alone. 
Abbreviations: EFS= Event-Free Survival, TTNLT = Time to Next Lymphoma Treatment, TTNCT = Time to Next Chemotherapy, OS = Overall Survival, PFS = Progression-Free 





Aspirin is also one of the most commonly used drugs in Europe and North America, used 
regularly by approximately half of the adult population according to a recent nationwide US 
survey.56 The most common indication is as a platelet inhibitor in the secondary prevention of 
cardiovascular disease. Aspirin has anti-inflammatory properties through the inhibition of 
cyclooxygenase 2 (COX-2), thereby inhibiting prostaglandin (Pg) biosynthesis. 
Prostaglandins, most notably PgE2, are necessary for carcinogenesis and tumor 
proliferation.57,58 The inhibition of prostaglandins would thus offer a possible explanation for 
the reduced cancer incidence seen in pooled randomized controlled trials (RCTs) of aspirin 
use for cardiovascular prevention.59 An alternative protective mechanism may be through 
inhibition of COX-1, which create an antiplatelet effect that potentially modifies the tumor 
microenvironment by releasing antiangiogenetic agents, diminishing tumor aggressiveness 
and proliferation.60 The most evidence for cancer preventive properties of aspirin have been 
found in colorectal cancer, which has been reported by several clinical and epidemiological 
studies. Among the first cohort studies in America to report this were the Nurses’ Health 
Study and the Health Professionals’ Study.61-63 
2.3.1 Aspirin and risk of lymphoma 
The observed associations between aspirin use and NHL risk have been more mixed. In the 
pooled RCTs of aspirin use for cardiovascular prevention discussed above, a statistically 
significant reduction in risk of lymphoma overall was seen for aspirin users, but data was too 
sparse to allow for subtype-specific analyses.59 Some authors have suggested that the 
associations may vary by lymphoma subtype. The largest prospective cohort study published 
so far reported a null association for NHL overall but an increased risk for the subtype of 
follicular lymphoma (FL).64 An overview of previously published studies with prospectively 
collected data that assess aspirin use and risk of lymphoma is presented in Table 2.3. 
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Table 2.3 Prospective studies on aspirin and risk of lymphoma 
Author Title Data source Study population Findings 
Cerhan.  
Int J Cancer 2003 65 
Association of aspirin and other non-
steroidal anti-inflammatory drug use 





27,290 women, 1992–99 
132 NHL cases 
Suggestive positive association between NHL overall and use 
of non-aspirin NSAIDs or non-aspirin NSAIDs and aspirin, but 
no association with aspirin use alone. 
Jacobs.  
JCNI 200766 
A Large Cohort Study of Long-Term 
Daily Use of Adult-Strength Aspirin and 
Cancer Incidence 
Cancer Prevention 
Study II Nutrition 
Cohort 
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Abbreviations: NHL= non-Hodgkin lymphoma, NSAID= Non-Steroidal Anti-inflammatory Drug, FL= Follicular Lymphoma, HR= Hazard Ratio, CLL= Chronic Lymphocytic Leukemia, 
SLL= Small Lymphocytic Lymphoma 
 
12 
2.4 PRIMARY CNS LYMPHOMA 
As mentioned initially, the vast majority of PCNSL (>90%) are of the DLBCL subtype, and 
most commonly of non-germinal center (non-GC) type.68 They usually have a very high 
proliferative activity with Ki67 of 70–90%. In immunocompetent patients the tumor most 
often is EBV early RNA transcripts (EBER) negative. PCNSL occurs more frequently in 
immunocompromised individuals such as patients with immunodeficiency syndromes,69 
organ transplant recipients receiving immunosuppressive therapy, and in particular in 
association with HIV, where PCNSL is one of the four defining malignancies for acquired 
immunodeficiency syndrome (AIDS).  
The incidence of PCNSL increased coinciding with the HIV epidemic until the mid-90ies and 
several reports from other parts of the world have suggested an increasing incidence even 
after that.13,14,70 However, population-based levels of both incidence and survival of PCNSL 
are strongly influenced by cases in HIV positive individuals, and the corresponding incidence 
and survival in immunocompetent PCNSL have been difficult to unravel. 
PCNSL poses particular clinical problems due to its location in the brain. It may be 
associated with substantial neurological symptoms, and can be hard to reach for biopsies and 
histological diagnosis. Despite high chemo- and radiosensitivity, it is challenging to treat and 
has a dismal prognosis. Most used radiotherapy regimens have caused severe sequelae, and 
the blood brain barrier has made it hard to access with conventional chemotherapy. 
Chemotherapeutic agents used in PCNSL treatment must be able to cross the blood-brain 
barrier and reach therapeutic concentrations in the CNS, either in conventional doses like 
corticosteroids, or like methotrexate (MTX), to able to do so in escalated, rapid intravenous 
doses. During the first decade of the 2000s, different regimens including high-dose 
methotrexate (HD-MTX) were introduced, where leucovorin rescue is used to interrupt the 
MTX effect outside the CNS, enabling higher doses of MTX to reach the CNS. These 
regimens have shown promising results in RCTs but, in addition to leucovorin rescue, they 
require pre- and post-hyperhydration, urine alkalinization, and MTX concentration 
monitoring, and thus careful balancing of this therapy intensification with side-effects control 
is needed71. 
In this thesis, we wanted to investigate a possible increasing incidence of immunocompetent 
PCNSL in the Swedish population, and also to evaluate if the new treatment schemes 





3 RESEARCH AIMS 
3.1 SPECIFIC AIMS  
Study I 
To assess if statin use is associated with improved myeloma-specific survival for patients 
with MM. 
Study II 
To assess if statin use is associated with improved lymphoma-specific survival for NHL 
patients overall or those with common subtypes including CLL.  
To assess if concomitant statin use during rituximab treatment is associated with decreased 
lymphoma-specific survival in patients treated with rituximab. 
Study III 
To investigate if aspirin use is associated with the risk of developing NHL or common 
subtypes. 
Study IV 
To characterize the epidemiology of PCNSL among immunocompetent individuals by 
investigating if an increased incidence can be established in the past 15 years in Sweden.  
To investigate if any survival benefits can be observed in a population-based setting 
following the development of intensified treatment regimens.  
3.2 HYPOTHESES 
Study I  
Statin use will be associated with improved myeloma-specific survival. 
Study II  
Statin use will be associated with improved lymphoma-specific survival in NHL patients 
overall or those with common subtypes including CLL. 
But patients treated with rituximab will have contrasting decreased survival based on a 
hypothesized interference of statins with rituximab treatment. 
Study III 
Aspirin use will be associated with a reduced incidence of NHL or subtypes. 
Study IV 
The recent incidence of PCNSL in Sweden will demonstrate increasing rates. 





4 MATERIALS AND METHODS 
4.1 DATA SOURCES 
Studies I, II and IV in this thesis use data from the Swedish population-based registers, 
whereas study III uses American cohort data. In this chapter, I will briefly describe these data 
sources. The Swedish population registers date back to the 17th century when the Swedish 
church started local registers of their parish members. Since 1991, the Swedish Tax Agency 
has the responsibility for this national registration. In addition, many new registers were 
started during the 20th century, including many with healthcare data. Since 1947, all Swedish 
citizens are assigned a personal 10-digit identification number (PIN) at birth or at registration 
if immigrating to the country.72 This PIN code enables linkage between the registers, creating 
excellent possibilities for register-based medical research. The registers are somewhat 
different in administration and coverage, and the ones used in this thesis are the following: 
The Swedish Cancer register was founded in 1958 and is held at the National Board of 
Health and Welfare. It includes information about all incident malignant diseases, including 
some benign tumors, in Sweden.73 In addition to the personal information (PIN, age, sex), the 
register contains date of diagnosis and hospital, as well as the diagnosis by International 
Classification of Disease (ICD) code. For diagnoses from 1993 it also contains the more 
detailed histopathology codes according to the Systematized Nomenclature of Medicine 
(SNOMED). The register has a dual reporting system by law, where both the physician 
diagnosing a malignant condition and the pathologist/cytologist answering a pathology report 
with a malignancy are obliged to report it to the register. This results in a high completeness 
and accuracy. According to a study performed among the lymphoid malignancies, their 
overall accuracy was 98% and completeness a bit more varying by aggressiveness of the 
malignancy, 98% for NHL overall, 97% for myeloma and slightly lower for indolent 
lymphoma such as CLL, 87%.74 Studies I, II and IV use data from this register. 
The Swedish Lymphoma register (SLR) is a quality register established in 2000, and 
includes all NHL diagnoses except CLL (that has its own quality register). The SLR contains 
detailed records of patient- and lymphoma-specific factors such as age at diagnosis, subtype 
according to SNOMED, diagnostic method, localization of the tumor and factors relevant to 
calculation of international prognostic index (IPI) score (disease stage, presence of elevated 
serum lactate dehydrogenase [LDH], performance status according to Eastern Cooperative 
Oncology Group (ECOG), and presence and specification of any extranodal manifestations). 
From 2007 onwards the SLR also contains information on treatment type as reported by 
clinicians in a specific electronic form. The coverage of the SLR has been reported to be 
>95% as compared to the Swedish Cancer Register.75 Studies II and IV use data from this 
register. 
The Swedish Cause-of-Death register was founded in 1961 and is kept by Statistics 
Sweden.76 It contains information on all deaths in Sweden based on the causes of death 
reported on the death certificate issued by the physician stating the death. Following a 
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definition by WHO an underlying (or “main”) cause of death is chosen depending on the 
severity, combination and order of causes of death listed on the death certificate. This process 
is facilitated by the Automated Classification of Medical Entities (ACME), a specific 
international algorithm provided by the US National Center for Health Statistics. While the 
Cause-of-death register is considered almost 100% complete in terms of the actual death and 
date of death, the accuracy of the underlying cause of death is more varying, reportedly 
highest among malignant disorders, where a validation study of the diagnoses in the register 
in 1995 found a 90% agreement with hospital data.77 Studies I, II and IV used data from this 
register. 
The National Patient register (NPR) was founded in 1964, with more complete coverage 
since 1987, and is administered by the National Board of Health and Welfare. It originally 
included the discharge diagnoses from all Swedish hospitals, thus inpatient diagnoses, now 
called The Swedish National Inpatient Register (IPR). A study from 2011 found that 99% of 
all hospital discharge diagnoses were registered in the IPR.78 From 2001, diagnoses from 
visits to physicians at non-primary outpatient care units are also included, a part called The 
Swedish National Outpatient Register (OPR). The completeness of this register is lower but 
no recent validation data are published. However, comparisons with statistics of outpatient 
visits from ”Sveriges kommuner och regioner” (SKR) approximate that somewhere between 
1-29% of the non-primary outpatient care is not covered in the register during the period 
2005-2018, with missing data mainly in the early years and from visits in the private sector 
(personal communication, statistician Karin Skölding at the National Board of Health and 
Welfare). Both the IPR and OPR contain main and contributing ICD codes from hospital 
discharge/doctors’ visits together with information about clinic and date. Studies I, II and IV 
used data from this register. 
The Longitudinal integration database for health insurance and labor market studies 
(LISA) was established in 1990 and is maintained by Statistics Sweden.79 The data are 
collected from several national registers with detailed individual socioeconomic information, 
including highest attained level of education, available in >98% of individuals aged 25-64 
years, with an estimated accuracy of 85%.79 Studies I, II and IV used data from this register. 
The Prescribed Drug register (PDR) was established in July 2005 and contains data on all 
dispensed prescriptions at Swedish pharmacies.80 Each dispensed drug is listed with product 
name, type of medication according to the Anatomical Therapeutic Chemical Classification 
System (ATC code), strength, pack size, prescribed quantity/number of packages and date of 
prescription and purchase. Medications administered at hospitals and all over-the-counter 
medications are not included in the register. For prescribed medications, however, the 
reporting to the register is automated, and the completeness is considered very high. Missing 
variables are reported to be found in only 0,2-0,4% of the individuals, slightly higher among 
antibiotic and antiparasitic medications, up to 1,4% (2019 data). Studies I and II used data 
from this register. 
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The Total Population register (TPR) was started in 1968 and is held by Statistics Sweden.81 
It contains data on all citizens of Sweden, including births, deaths, immigration and 
emigration, and an updated version is provided monthly. Virtually all births and deaths are 
reported to this register within 30 days. A slightly lower capture of immigration and in 
particular, of emigration, results in an estimation of up to 0,5% over-coverage of TPR.81 
Studies I and II used immigration and emigration data from this register. 
The Cancer incidence database (Statistikdatabasen), a publicly available cancer incidence 
database, held by Statistics Sweden. Study IV used data from this database.  
The Human Mortality Database (HMD) is an international database that began in year 
2000 as a collaboration between the Department of Demography at the University of 
California, Berkeley, USA and the Max Planck Institute for Demographic Research in 
Rostock, Germany. HMD was created in order to provide detailed mortality and population 
data and currently includes data from 41 countries or areas. Statistics Sweden provide 
Swedish data to HMD. Study IV used data from this database.  
In the US, the National Death Index was established in 1979 by the National Center for 
Health Statistics, in order to provide collected information on deaths and causes of death from 
the different states. Other health information, however, is less coordinated. Data about health 
services and drug dispensations are divided in different systems of health plans or insurance 
providers. Instead, medical researchers have used other approaches for data collection, among 
them several ambitious cohorts.  
The Nurses’ Health Study (NHS) was established in the seventies when the oral 
contraceptives became increasingly used, and researchers wanted to assess possible long-term 
consequences such as cardiovascular disease and breast cancer. Nurses were chosen as 
participants because of their dedication to human health and their medical knowledge, and as 
they were expected to be able to provide accurate information about medications and health 
issues. Only married nurses were included, as oral contraceptive use was sensitive at the time. 
So in 1976, 121,700 female, married, US registered nurses aged 30 to 55 years and residing 
in any of the 11 most populous US states, returned an enrollment questionnaire.82 Since then 
biennial follow-up questionnaires have updated cohort members’ information on an extensive 
number of risk factors and diseases. The response rate of the questionnaires has been ≥90% in 
most follow-up cycles.  
The original focus of the cohort study was contraceptive methods, smoking, cancer and 
cardiovascular disease, but additional questionnaires have been added covering other life-
style factors including dietary information, quality of life questions, as well numerous 
additional diseases and medications. As an example, detailed prospective data on regular use 
of aspirin, including over-the counter-use, is now available for >25 years of follow-up (Fig 
4.1). Biological samples have later been added as well, such as blood, urine and buccal 
mucosal cells. Two off-spring cohorts have also followed, the NHS2, established in 1989, 
aiming to cover nurses that started contraceptive use earlier in their adolescence and study a 
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broader range of premenopausal risk factors and outcomes, and NHS3, initiated in 2010, 
aiming to include nurses from more diverse ethnical backgrounds and capture more current 
exposures and habits, also including other healthcare workers, both men and women. NHS3 
is also the first NHS cohort to be entirely web based. 
The quality of the NHS database is high, NHS staff perform reviews of medical records and 
pathology reports in order to confirm diagnoses self-reported by the participants. When 
medical records are not available, linkage to applicable cancer registers is used. Deaths 
among cohort members is identified by next-of-kin or by periodic searches of the National 
Death Index,83,84 similarly followed by medical record review or linkage to state cancer 
registers to confirm cause of death or previously unreported diagnoses. Data from this cohort 












Fig 4.1 Parts of the 1980 and 1990 NHS study questionnaires, showing the sections including 
the questions regarding aspirin use. Used with permission of NHS responsible Meir Stampfer 




4.2 STUDY DESIGNS AND STUDY POPULATIONS 
4.2.1 Cohort study  
All the studies in this thesis use, at least in part, a cohort study design, although the types of 
cohorts differ slightly (Table 4.1). A cohort study is a study design in which a designated 
group of individuals are followed-up for exposures and outcomes over a well-defined period 
of time of time.85 It measures and compares occurrence (i.e. incidence) of the outcome (i.e. 
disease). The selection or classification of subjects is based on exposure status, (i.e. citizens 
of Sweden or nurses in 11 US states). In an observational cohort study the investigator does 
not assign the exposure. The participants must be free of the outcome at beginning of follow-
up, and must be at risk of developing the outcome. 
4.2.2 Case-control study 
This study design was used within the cohorts of studies I and II, more specifically the so 
called nested case-control study design. In a cohort study it is sometimes hard to obtain 
sufficient numbers of outcome events for a rare outcome, or it may be expensive or, as in our 
case, difficult to obtain or categorize exposure information from everyone in the cohort. Then 
a case-control study design may be more efficient.86 Instead of, as in a cohort study, choosing 
participants based on their exposure status and compare the exposed participants against the 
unexposed, in a case-control study we select subjects that develop the outcome of interest 
(cases) and compare their exposure to that of the subjects that do not develop the outcome 
(controls). Controls are a sample from the source population that gave rise to the cases, and 
provide an estimate of the exposure in the source population. The key is to select controls 
independently of their exposure status, otherwise we may introduce selection bias. Further 
limitations with a case-control study is that there may be reduced precision due to sampling, 
although this loss can be kept small if the number of controls selected per case is large. 
Unless time at risk is incorporated in the sampling, case control studies cannot directly 
measure risks or rates, instead Odds Ratios (ORs) is the only measure of association that is 
possible to calculate directly from any case-control study. However, if we sample our 
controls with risk set sampling, so that controls are matched to cases on time, the ORs equals 
Hazard Ratios (HRs).86 In risk set sampling, the controls are sampled with replacement from 
a unique set of people in the source population who are at risk at the time each case is 
diagnosed. Thus, the risk set therefore changes from one case to the next, and theoretically a 
control can later become a case, and the same control may be selected by chance more than 






4.3 CLASSIFICATION OF EXPOSURES AND OUTCOMES  
4.3.1 Statin exposure 
In studies I and II, all statins available in Sweden during the study period were included: 
simvastatin, pravastatin, fluvastatin, atorvastatin and rosuvastatin. Persons with at least one 
dispensation of a statin during the 6-month period before diagnosis were considered statin 
users at time of diagnosis, and persons with at least one dispensation during the period six 
months after diagnosis were considered statin users after diagnosis. We also assessed statin 
use at any time during follow-up in a nested case-control study, for which all statin 
dispensations during the period from diagnosis until six months before index date (death of 
the case) were included.  
Statin dose intensity was classified according to the American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines,87 depending on the average 
mg/day dispensed during the period of interest. The ACC/AHA guidelines are based on 
pooled data from numerous RCTs of statin use in cardiovascular prevention, and categorize 
statin therapy into low, moderate and high intensity therapy corresponding to the average 
decrease of serum low-density lipoprotein cholesterol (LDL-C) attained with the respective 
statin dose (Table 4.3).   
Table 4.3 ACC/AHA categories of statin therapy intensity 
Intensity LDL-C reduction Included statins and doses 
Low intensity  <30%   Simvastatin 10-15 mg  
Pravastatin 10-30 mg 
Fluvastatin 20-60 mg  
Moderate intensity 30 to <50% Atorvastatin 10-30 mg  
Simvastatin >15-80 mg  
Pravastatin>30-80 mg  
Fluvastatin >60-80 mg  
Rosuvastatin 5-15 mg 
High intensity ≥50% Atorvastatin >30-80 mg  
Rosuvastatin >15-40 mg 
Abbreviations: ACC/AHA = American College of Cardiology/American Heart Association,  
LDL-C = Low-density lipoprotein cholesterol 
Duration of statin use was calculated from time of first dispensation until six months after the 
last dispensation. If new dispensations occurred after that, they were added to the total 
duration. In Sweden, a dispensation by practice covers three months of use, so this allowed 
for some missed doses or uneven distribution of purchases. 
4.3.2 Aspirin exposure 
Questions about aspirin use were first queried in the 1980 NHS questionnaire, and thereafter 
in every questionnaire except in 1986. Of note, the question has been posed differently in 
different years, and a specific question separating low dose aspirin, “baby” aspirin (81 mg in 
the US) from high dose “adult” strength (325 mg) was not introduced until 2000, thus too late 
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to allow separate examination of low and high dose aspirin. In order to extract as much 
information as possible from the available data, we defined aspirin use in three ways in study 
III: 
1. Current status regarding regular use of the equivalent of two “adult” strength (325 
mg) tablets/week, classified as yes/no. 
2. Cumulative average quantity of use (nonuse, <2, 2-<5, 5 tablets/week), for which we 
determined the average number of adult strength tablets/week at baseline and then 
computed an updated average each biennial follow-up cycle. 
3. Duration of regular aspirin use, for which we summed the consecutive years of 
regular aspirin use reported (nonuse, 5, 6-10, 11 years).88  
If aspirin information was missing on a questionnaire, the information from the previous 
questionnaire was carried forward. If the information was missing for two or more 
consecutive questionnaires, the variable was set to missing. 
4.3.3 Disease-specific mortality 
In study I the outcome was myeloma-specific mortality and in study II lymphoma-specific 
mortality, defined as any plasma cell- or lymphoma ICD10 codes respectively, as main 
(underlying) cause of death. In order to validate these outcomes, we also compared these 
causes of death in a subset of the patients to the information provided in medical records. For 
this, we followed an algorithm used previously in pediatric cancer.89,90 
4.3.4 Relative survival and excess mortality 
Relative survival (RS) is used as an outcome measure in study IV. RS is the ratio of the 
observed all-cause survival of a cohort of, in our case, PCNSL cancer patients to the expected 
survival of a comparable group of individuals in the general population that are assumed free 
of PCNSL.91 So called life tables are typically used to represent the expected survival of the 
general population. We assume that the cancer patients would be exchangeable to the general 
population, had they not been diagnosed with cancer, so that the difference in mortality 
between the cancer and the cancer-free groups is explained by the PCNSL. The fact that the 
cancer patients are included also in the general population has been shown to introduce a very 
small bias in estimates of relative survival given that the proportion of e.g. PCNSL patients in 
the general population is so small.92 In contrast to disease-specific survival/mortality, relative 
survival incorporates also indirect cancer mortality, such as treatment related mortality or 
mortality associated with other factors related to the cancer. 
Excess mortality is the mortality analogue of relative survival, and is also used in study IV. It 
is defined as the ratio between the mortality rate in the group under observation, the PCNSL 
patients, compared to the general population.91 The excess mortality can be modelled and 
contrasted by various groups using Poisson regression. In this setting the excess mortality rate 
ratios provide estimates of the relative difference in excess mortality between the groups. As 




4.3.5 Diagnosis of NHL subtypes 
Diagnoses of NHL in study III were self-reported by the women in the NHS cohort in the 
biennial questionnaires. The NHS staff then reviewed medical records and pathology reports 
in order to confirm the diagnoses. If this confirmatory data could not be accessed, linkage to 
applicable cancer registers was performed. Diagnoses of NHL from the period before the 
revised WHO classification of hematological diseases of 2008 were reassessed and 
reclassified according to the 2008 WHO classification and the guidelines of the International 
Lymphoma Epidemiology (InterLymph) Consortium Pathology Working Group.93,94 In our 
analysis we included all confirmed primay incident diagnoses of NHL (ICD-8 codes 200, 
202, 204.4), including CLL, but not multiple myeloma, that has been published earlier.95  
4.4 STATISTICAL METHODS 
4.4.1 A brief introduction to the methods and tests used in this thesis 
When we want to estimate the association between an exposure (such as statins or aspirin) 
and an outcome (such as diagnosis of a lymphoid neoplasm or disease-specific death) in an 
observational study, we often need to adjust for several potential confounding factors, in  
multivariable models. Depending on our study design and research question there are several 
statistical methods we can use. Below, I will briefly discuss the rationale behind the methods 
used in this thesis as well as some of the statistical tests used.  In several studies we will 
interpret and express the relative rates of the outcome obtained from the regression models as 
a relative risk. 
Cox proportional hazards models (or Cox regression) are used in studies I, II and III in 
which we have a binary outcome with variable follow-up time and censoring.96 Cox 
regression is the most common method for survival analysis. It estimates the ratio of the rates 
of the outcome (i.e. rate of diagnoses of lymphoid neoplasm or death) for the exposed / 
unexposed over time, the hazard function, and the outcome measure is Hazard Rate Ratio. 
With a Cox model, it is possible to evaluate the associations with several covariates at the 
time, upon the time it takes for the outcome to occur. The Cox model does not give us the 
baseline hazard, but the ratio of the hazards of the groups we compare. The levels of the 
variables we compare can change over time if we include time-varying covariates, but the 
model makes the assumption that the hazard ratio of the groups we compare is constant 
during the follow-up, i.e. the proportional hazards assumption. If this assumption is not 
satisfied, our results may not be valid.  
Conditional logistic regression is used in the nested case-control analyses in study I and II. 
Logistic regression is suitable when we have a binary outcome and do not explicitly take 
follow-up time into account (in our case we used risk set sampling, thus conditioned or 
matched on time, so time is accounted for implicitly by the study design).97 The outcome 




Kaplan Meier curves were used in study I and II to visualize univariate cumulative survival 
estimates. Using this method it is not possible to adjust for confounders so this type of graph 
needs to be interpreted with much caution in observational studies. 
Flexible parametric survival models were also used in study I and II in order to visualize 
adjusted survival graphs in comparison to the univariate, given that graphs are not possible to 
attain with the Cox models we used in our main analyses.98  
Likelihood ratio tests were used in study I in order to evaluate any effect modification by 
sex. This test assesses the goodness of fit by comparing the log likelihoods of two competing 
nested statistical models, in this case where one is also adjusting for sex, and the other is not. 
Positive Predictive Value is the number of true positive tests (or in our case, accurate 
diagnoses) divided by all the positive tests (or diagnoses), both true and false. This test was 
used in study I and II. 
Poisson regression is used in study IV to estimate incidence rates of PCNSL. Poisson 
regression is typically a model for count outcomes but can also be adapted to accommodate 
survival data. This type of regression model assumes a Poisson distribution for the events, i.e. 
PCNSL diagnoses, because the event occurs equally likely at any point in time, and the 
probability of an event occurring is proportional to the length of time you wait.99 For 
modelling the incidence rates (PCNSL diagnoses / person-time at risk), the risk time is 
incorporated in the model as an offset term (i.e. a constant that can vary from individual to 
individual). 
Population attributable fraction is the proportion (fraction) of all cases in the population 
that can be attributed to the exposure. Or mathematically: (proportion of cases exposed) x 
(attributable proportion in the exposed). This test is used in study IV. 
4.4.2 Methods by study  
The study methodology applied in studies I and II is similar. The rationale behind these 
studies is the same, to investigate the associations between statin use and prognosis in 
lymphoid malignancies in a population-based setting. Because lymphoid malignancies are 
heterogeneous, with different treatments and putative mechanisms of association with statin 
use and different research questions, we decided in accordance with suggestions at the half-
time seminar, to pursue these different research questions further in two different studies. In 
MM, with the only large published study being performed in American veterans of whom 
98% were male,32 we wanted to assess if population-based results were the same, and 
specifically if there was any effect modification by sex. We also wanted to assess whether a 
prior diagnosis of MGUS affected any possible association between statin use and survival. 
In NHL on the other hand, given the large differences by subtype in molecular biology and 
clinical course, we wanted to separate as many distinct subtypes as possible making use of 
the detailed histologic information available in the SLR. We also wanted to adjust NHL 
models for age-adjusted IPI score and whether active lymphoma treatment was started or not. 
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Furthermore, given previous in vitro data,34 we wanted to assess whether there were 
indications of increased mortality in association with rituximab, one of the most frequently 
used treatments in lymphoma, but not used at all in MM. Beneath, I will describe the methods 
for study I, and then point out modifications done in study II. 
Study I included all incident multiple MM diagnoses from 2007-2013 identified via the 
Swedish Cancer register 2007-2013. We followed the patients until the earliest among dates 
of death, emigration or December 31st 2013. Information on dates and causes of death was 
added from the Cause-of-Death register and socioeconomic data were retrieved from the 
LISA database.79 Data on use of statins and other medications were retrieved from the 
Prescribed Drug register. Data on any previous MGUS and number of non-primary care 
doctors’ visits during the 3-year period prior to diagnosis were retrieved from the Swedish 
inpatient and outpatient registers.  
We used Cox proportional hazards models to contrast the risk of the primary outcome 
myeloma-specific mortality and secondary outcome all-cause mortality for statin users 
compared to non-users, using HRs and 95 % CIs. Analyses were calculated for statin use 
before and after diagnosis of MM respectively (as described previously, see “Exposure 
classification” section). In analyses of statin use during the period six months after diagnosis 
we used a 6-month exposure lag. We thus applied an additional six months delayed entry 
(beyond the 6 months exposure assessment period) in the analyses, after start of the timescale 
at time of MM diagnosis. Models were adjusted for age at diagnosis, sex, year of diagnosis, 
education level and concomitant medication with anticoagulants, diuretics, beta-blockers, 
ACE inhibitors, calcium blockers and anti-diabetics to capture comorbidity. In sensitivity 
analyses in order to assess potential healthy user bias we also adjusted for use of PPIs and 
SSRIs and number of non-primary care doctors’ visits during the 3-year period before 
diagnosis. Separate analyses were also made for patients with previous MGUS diagnosis and 
we also performed analyses stratified by sex and formally tested potential effect modification 
by sex using a likelihood ratio test for the interaction parameters.  
In order to assess statin exposure at any time during follow-up, we performed a 1:5 matched 
nested case-control analysis where all “cases” (myeloma-specific deaths) were matched to 
five controls, defined as participants of the cohort that were still alive and at risk at the date of 
the death of the case (index date). In this analysis, all statin dispensations during any time 
from diagnosis until 6 months before index date were included. A sensitivity analysis 
omitting a longer period before index date was also performed, thus including statin 
dispensations only up until one year before death of the case. 
We also performed dose-response analyses assessing intensity of statin use (low, moderate, 
high) and performed trend tests across categories of dose intensity. In the nested case-control 
sample we also performed analyses of duration of statin use with trend tests. 
Study II included all incident NHL patients identified in the SLR, and CLL patients 
identified in the Cancer register from 2007-2013. For persons with two or more lymphoma 
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diagnoses during follow-up, only the first chronological diagnosis from the SLR and/or 
cancer register was included in the cohort. If two different NHL diagnoses were reported on 
the same day, we considered them discordant. 
Methods were similar to study I, using multivariable Cox proportional hazards models to 
compare rates of the primary outcome lymphoma-specific mortality and secondary outcome 
all-cause mortality for NHL overall, for subtypes, and for CLL. The same covariates as in 
study I were included in the models, and because of the detailed information in the SLR, we 
were also able to adjust for additional patient and disease characteristics in all models except 
CLL models. The risk factors included in the calculation of the international prognostic index 
score (IPI), including age, disease stage, presence of elevated serum lactate dehydrogenase 
[LDH], performance status according to Eastern Cooperative Oncology Group (ECOG), and 
presence and specification of any extranodal manifestations, were in the models as an age-
adjusted IPI score. In all models except CLL and the stratified FL models we also adjusted 
for whether active lymphoma treatment was started or not. In order to investigate patients 
with or without rituximab treatment separately, we assessed the patients with FL that started 
treatment at diagnosis separately from those FL patients that did not start treatment but were 
instead followed with a watch-and-wait approach. We chose this subtype because of the 
uniform treatment recommendations in Swedish guidelines where rituximab is included in the 
treatment for all patients with indication for systemic treatment. 
We performed a nested case-control analysis similar to the one in study I, except that in study 
II, we also matched on subtype. We also performed intensity and duration analyses similar to 
study I. In study II however, we also performed sensitivity analyses requiring two 
dispensations per 6-month period in order to be categorized as a statin-user. We also explored 
categorizing statin use in slightly different periods around the time of diagnosis (statin before 
diagnosis as dispensations 9-3 months before diagnosis), and we explored different exposure 
lags (3 and 9 months). 
Study III was conducted in the Nurses’ Health Study cohort (NHS). We included all women 
who answered the earliest relevant questions on aspirin use in the 1980 questionnaire and 
excluded those with a baseline history of cancer or RA. We followed the participants until the 
earliest among dates of NHL or other cancer diagnosis, diagnosis of RA, death or close of 
follow-up June 2012. We calculated HRs and 95% CIs using multivariable Cox proportional 
hazard regression models stratified by follow-up period and attained age (in months) to 
estimate the relative risk of NHL overall and of major subtypes DLBCL, FL, CLL and T-cell 
lymphoma associated with current regular aspirin exposure status and cumulative average 
quantity and duration of use (as described in the exposure classification section). Models 
were adjusted for potential confounding by region of residence, race, current BMI, smoking 
status and alcohol consumption and a 4-year exposure lag was applied in the analyses.  
We also performed trend tests across categories of quantity and duration of aspirin use in 
order to assess dose-response relationship. Tests for trend were performed based on an 
ordinal version of the aspirin use variables, created from the category medians. 
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In the restricted follow-up period for which data were available (1994-2012), additional 
sensitivity analysis models were adjusted for concurrent use of acetaminophen and NSAIDs 
(yes, no). 
Study IV included all incident cases of PCNSL from 2000-2013, identified in the SLR. To 
estimate any underreporting to the SLR we linked to an external case-series of confirmed 
PCNSL from the Uppsala region100 and a clinical series from the Stockholm region in 
Sweden. Immunodeficient PCNSL-cases were identified through the Swedish Patient register 
and excluded. Date and causes of death were obtained from the Cause-of-Death Register. We 
calculated incidence (per 100,000 person-years) and 95% CIs by age, sex and calendar 
period, and used relative survival to estimate PCNSL-specific survival. The expected survival 
was obtained from publicly available life tables. We performed tests for temporal trends in 
excess mortality using Poisson regression. We used Statistikdatabasen to assess general 
trends in incidence of all brain tumors in Sweden over the study period, as a reflection of 
diagnostic intensity of malignancies with CNS location.  
We calculated cumulative relative survival by sex, age at diagnosis, calendar period of 
diagnosis, and performance status and plotted graphs. We also used Poisson regression to 
estimate excess mortality rate ratios (EMRR) to contrast PCNSL-specific survival in these 
patient subgroups. We formally tested for statistically significant differences in excess 
mortality by subgroups using likelihood ratio tests. 
4.5 METHODOLOGICAL CONSIDERATIONS 
The Swedish population-based registers provide a great source of real-world evidence, but as 
in all observational research, methodological considerations are essential for the validity of 
our studies. When assessing potential associations with drug use in an observational study 
there are several possibilities, including multiple potential sources, of bias and exposure 
misclassification. Reverse causation (or protopathic bias), confounding by indication and 
immortal time bias are examples of biases with particular relevance in the studies of this 
thesis.101  
Exposure classification is essential in pharmacoepidemiology. The plausibility of an 
association is strengthened by presence of a dose-response relationship and/or duration of 
use.102 As for the dose intensity, the Swedish drug register contains a variable for defined 
daily dose (DDD). The DDD is the assumed average maintenance dose per day for a drug 
used for its main indication and it is decided by the WHO Collaborating Centre for Drug 
Statistics Methodology (WHOCC) in Oslo, Norway.103 The DDD would be the most 
accessible way to categorize statin exposure, but it is a unit of measurement that does not 
necessarily reflect the recommended or prescribed daily dose. For statins, the treatment 
intensity has been increasing over time, and the WHOCC has changed the DDDs twice, last 
in 2009 in order to reflect the changing prescription patterns. Furthermore, the different 
statins are not equipotent, making comparisons between the different types difficult. 
Numerous studies have been published about statins and cancer using DDDs to classify 
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intensity. The reasons for this are obvious: apart from being easily accessible the DDD is also 
easy to quantify and very few authors have had access to actual lipid levels in cancer 
patients,47,54 given that this is not a variable included in the work-up for cancers. Although the 
correlation between levels of blood cholesterol and cancer is not known, it is reasonable to 
expect that any association with statin dose intensity would be correlated with the degree of 
reduction of blood cholesterol, as has been shown in cardiovascular disease.104  
Using the ACC/AHA categories posed other challenges, however. Given that the different 
statins are not equipotent, the mean statin dose as a basis for mean intensity could not be 
used, instead the mean intensity needed to be recalculated every time a person changed statin 
ATC type. This made the time-dependent statin intensity categorization complicated, and 
because of this we finally decided to use a nested case-control study design rather than Cox 
models with time-dependent exposure of statin intensity categories when assessing exposure 
during the entire follow-up. In those nested case-control analyses, persons changing ATC 
code were evaluated manually. 
Reverse causation, arises when the occurrence of the outcome leads to changes in the 
exposure or the way the exposure is measured. A common form of this is protopathic bias in 
pharmacoepidemiologic studies.101 Potential examples of this in the thesis include that early 
symptoms of indolent lymphoma may give pain, causing the patient to use aspirin or other 
NSAIDs. This could create a false association between aspirin use and lymphoma risk, 
whereas in reality the initiation of the medication was a consequence of the outcome of 
interest even though the outcome was still undiagnosed.  
Another example is that patients with malignant disorders may stop taking prophylactic 
medications such as statins when they are approaching the end of life.105-107 This would create 
an association where non-use of statins would seem associated with reduced mortality, when 
in fact entering the late palliative phase causes the patient to stop the medication.  
Both of these examples would thus induce false associations with the respective medications 
if not addressed properly. In the first example, one possibility to address this bias is by not 
classifying a person as having been “exposed” to aspirin until a certain amount of time has 
passed after the actual initiation of the medication, a so called “exposure lag”.108 In the statin 
example, the exposure period before the outcome (death) is where we expect the biased 
exposure to occur, and we need to exclude that exposure period in our analysis.109,110 In this 
case as well, by “lagging” the statin exposure classification six months, the last six months of 
the exposure are not included in our analysis.  
Challenges with this approach include making the right assumptions about time in order to 
use the right lag time. In the example of aspirin and lymphoma, we need to know how long 
before the clinical diagnosis of lymphoma a person may have symptoms causing them to take 
aspirin. We also need to make the right assumptions about how long the induction period is, 
i.e, how long does it take from one’s exposure to aspirin before it may influence the risk of 
the outcome, lymphoma, as well as the latent period, i.e. the time it takes from the lymphoma 
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develops until it gets diagnosed.108 Rothman calls the sum of these two periods the “empirical 
induction period”. He argues that the longer it is, the more it will attenuate the effect-estimate 
because of increasing nondifferential misclassification.108 Studies with exposures that have 
very long empirical latency periods will therefore get very different results depending on the 
length of the follow-up. 
Confounding by indication arises because individuals who are prescribed a medication or 
an intervention are inherently different from those who are not; they get the prescription for a 
reason. Statin users are different than non-users of statin in that they may have higher blood 
cholesterol or more cardiovascular disease, and the reasons for starting statin treatment may 
be associated with our outcome of interest rather than the statin medication itself. This is a 
bias that is hard to fully address, but a frequently used method to attenuate these differences 
between the exposed and the non-exposed, is to use Propensity Score Matching. This tool 
allows us to match subjects according to their propensity to be statin users or not and, in so 
doing, to account for the indication bias.111,112 However, this method only adjusts for the 
measured confounders included in the propensity score and not the unmeasured confounders. 
Also importantly and as discussed earlier, in a case-control study controls must not be 
selected based on their exposure status, so this method cannot be used in case-control studies. 
Immortal time is a bias arising from the differential inclusion of  “immortal person‐time”, a 
period of follow‐up during which outcomes cannot occur because of the treatment definition 
(Fig 4.5).113 In this thesis, when we define statin users as those filling at least one statin 
prescription during the 6-month period after diagnosis, if we would also start follow-up at 
diagnosis, all early deaths within the first few months would be assigned to the non-users, 
because the deaths occurred before some statin-users had filled their prescription. 
However, if the patients lived long enough to fill their prescription, this time would be 
counted as person-time for the statin-users. This unbalance creates a period of statistical 
“immortality” for statin users that first period of up to six months. When added across all 
statin users, the person-time for statin users has the potential to include a considerable amount 
of “immortal” person-time, adding substantially to the total person-time of the statin-users, 
thus falsely lowering their mortality as compared to the non-user group. Studies have shown 
immortal time bias to be unproperly addressed in several observational studies of cancer 
survival and adjuvant medications or procedures.114  
One way to adjust for immortal time bias is known as the landmark analysis, where we 
decide a (landmark) time point before which we assign/measure the exposure status, and after 
which we begin to count person-time for both the exposed and the unexposed, to avoid 
adding misclassified person-time to only one group.114 In study I and II, the analyses 
assessing statin use during the period 6 months after diagnosis are landmark analyses, as the 
exposure status gets assigned during those six months, and the accrual of person-time begins 
only after those six months (plus a 6 months lag-time). In a landmark analysis, it is important 
to choose the right landmark timepoint. If we chose it too early, we may misclassify some 
statin users that do not have dispensations during that time. If we choose it too late, we 
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postpone the starting point of accrual of person-time and we may lose several patients and 
limit our statistical power. 
In the landmark analysis however, we only make use of the exposure information during a 
short period of time. If we want to use the information about statin use during the entire 
follow-up, another way to avoid immortal time bias is to use time-dependent Cox models115, 
in which exposure status can change during follow-up, and person-time gets assigned to the 
corresponding category of exposure status. 
Fig 4.5 Immortal time bias is introduced in a cohort study when (top figure) the immortal 
time is either misclassified as time in the treated group in a time fixed analysis (although, by 
definition, if an event would have occurred during this period, it would have been attributed 
to the untreated group given that the person has not yet filled a prescription). It can also be 
introduced when (bottom figure) this person-time is excluded from the analysis, given that the 
start of follow-up is defined by the start of treatment it is by design later in the treated group 




4.6 ETHICAL CONSIDERATIONS 
The patients in studies I, II and IV in this thesis have been identified via Swedish population-
based registers and the quality register SLR. The registers have been linked at the National 
board of Health and welfare. They remove the personal identification number before sharing 
the data with the Division of Clinical Epidemiology, Karolinska Institutet, so that all data 
analyzed are pseudonymized. The only exception from this rule in this thesis (in which 
patients are directly identifiable) is the medical record review for the cause-of-death 
validation in study I (myeloma-specific death) and study II (lymphoma-specific death) in 
which we received the personal identification number for a small subset of the patients in 
order to access medical records and confirm or refute their reported cause-of -death. Given 
that these patients were all dead, an informed consent could not be asked. In addition, the 
validation part was performed by a physician at the hematology clinic at the Karolinska 
University Hospital, Stockholm, who only read the records necessary to adjudicate cause-of-
death. 
In order to process personal data there must be a “lawful basis for the processing”, otherwise 
it is not considered legal according to GDPR. There are six lawful bases mentioned in GDPR, 
of which “Processing is necessary for the performance of a task carried out in the public 
interest” is applicable in our studies. We thus believe the benefits of the knowledge gained 
are considered to outweigh possible harm to the patients in terms of breach of integrity. The 
information gained is of general interest to many patients and clinicians, and the data 
presented is not of sensitive nature. As for the validation study, in which data were not 
pseudonymized, the data were not sensitive, and the cause-of-death validation attained will be 
of help for the interpretation of these and other studies to come. 
Studies I, II and IV have been approved by the regional ethics review board at Karolinska 
Institutet. 
The patients included in study III were all identified in the NHS cohort described above. The 
electronic study data archives did not include personal identifying information on study 
participants but utilized a unique study ID to link relevant data to the corresponding 
individuals. Informed consent was implied by the voluntary return of study questionnaires. 
The protocol for the present study was approved by the Human Subjects Research 
Committees at Brigham and Women’s Hospital and the Harvard School of Public Health 







5.1 MAIN RESULTS OF STUDY I AND II 
In study I, we identified 4,315 patients with an incident diagnosis of MM, of whom 5.3% had 
a previous diagnosis of MGUS. There were 1,496 myeloma-specific deaths among 1,913 
deaths in total. In the cohort, 21% used statins during the 6-month period before diagnosis, 
“at baseline”, and 86% of the dispensed statins were simvastatin. During the 6-month period 
after diagnosis 17% used statins. Baseline use of statins was associated with a 17% reduction 
in myeloma-specific mortality (multivariable adjusted HR = 0.83, 95% CI: 0.71, 0.96) and a 
15% reduction in all-cause mortality (HR = 0.85, 95% CI: 0.75, 0.97) (Fig 5.1a), whereas use 
of statins during the 6-month period after diagnosis was associated with a 27% reduction in 
myeloma-specific mortality (HR= 0.73, 95% CI: 0.60, 0.89) and a 19% reduction in all-cause 
mortality (HR = 0.81, 95% CI: 0.69, 0.95) (Fig 5.1b). In the analysis of statin use during the 
6-month period after diagnosis and association with myeloma-specific mortality, we 
performed additional analyses with longer exposure lags (Table 5.1). This did not change 
point estimates considerably, but confidence intervals got wider. 
Table 5.1. Hazard ratios (HR) and 95% confidence intervals (CI) for the association of statin use and 
myeloma-specific and all-cause mortality in Sweden 2007-2013 with increasing exposure lags 
Statin use versus no use 
after diagnosis* 
Myeloma-specific mortality All-cause mortality 
 Model n-deaths/  
N subjects 
HR (95% CI) n-deaths/  
N subjects 
HR (95% CI) 
 Adjusted, 6 months lag 855/2,955 0.73 (0.60, 0.88) 1,123/2,955 0.81 (0.69, 0.95) 
 Adjusted 1 year lag 689/2,518 0.73 (0.59, 0.91) 879/2,359 0.84 (0.70, 1.01) 
 Adjusted 2 years lag 408/1,690 0.78 (0.59, 1.04) 535/1,690 0.78 (0.61, 0.99) 
 Adjusted 3 years lag 226/1,046 0.84 (0.58, 1.23) 284/1,046 0.87 (0.63, 1.21) 
 Adjusted 4 years lag 101/619 0.79 (0.45, 1.40) 125/619 0.77 (0.46, 1.28) 
Abbreviations: HR= Hazard Ratio, CI=Confidence interval, MM= Multiple myeloma 
*During the period 6 month after diagnosis 
Adjusted for age category, sex, year of diagnosis, highest education level, medication (yes/no) for: diabetes, 
anticoagulants, diuretics, beta-blockers, ACE inhibitors, Calcium channel blockers during same period as 
statin exposure. 
We performed sex-stratified analyses in which statin use was significantly associated with a 
lower myeloma-specific mortality in women (statin use after diagnosis; 0.57, 0.42-0.79) but 
not in men (0.87, 0.68-1.11), but there was no statistically significant interaction by sex when 
assessed formally, (P = .094). Sensitivity analyses restricting the patients to those without 
previous MGUS diagnosis yielded similar results. 
The case-control analysis of 855 cases of myeloma-specific mortality and 4,275 controls, 
showed that participants with a statin dispensation at least once at any time during follow-up 
had a 35% lower myeloma-specific mortality (HR 0.65; 95% CI 0.52-0.80) compared to non-
users (Fig 5.1c). The sensitivity analysis restricting statin exposure to dispensations up until 1 
year before index date did not substantially alter the results, although there was a slight 
attenuation (HR 0.71; 95% CI 0.56, 0.89). 
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In study II we identified 16,098 patients diagnosed with NHL (N=12,819) or CLL 
(N=3,279). The NHLs included 4,130 DLBCL, 1,751 FL (further divided into 989 FL 
starting treatment and 762 FL followed with a watch-and-wait strategy), 769 MCL, 766 
MZL, 130 Burkitt lymphomas, 952 T/NK-cell lymphomas, 755 LPL and 3,566 discordant 
and other lymphomas. There were 3,040 lymphoma-specific deaths among a total of 4,743 
deaths. In the cohort, 20% used statins during the 6-month period before diagnosis. 
Statin use during the period 6 months before diagnosis was not associated with lymphoma-
specific mortality in all NHL (multivariable adjusted HR = 0.95, 95% CI: 0.85, 1.06), CLL 
(HR = 0.91, 95% CI: 0.69, 1.21) or those with any other major NHL subtype, but for Burkitt 
lymphoma patients we observed a statistically significantly reduced lymphoma-specific 
mortality (HR = 0.19, 95% CI: 0.04, 0.83, n=20 statin users) (Fig. 5.1A).  
Likewise, statin use during the period 6 months after diagnosis was not associated with 
lymphoma-specific mortality in all NHL patients (HR = 0.93, 95% CI: 0.77, 1.12), CLL 
patients (HR = 0.79, 95% CI: 0.55, 1.12) or those with the other subtypes except for T/NK-
cell lymphoma patients, in whom we observed a statistically significant reduced lymphoma-
specific mortality (HR = 0.42, 95% CI: 0.18, 0.98). The post-diagnosis statin use in Burkitt 
lymphoma could not be assessed due to sparse numbers. When stratifying FL patients by 
treatment or the watch-and-wait approach, lymphoma-specific mortality was not significantly 
different for statin users compared to non-users among actively treated patients (HR = 0.87, 
95% CI: 0.45, 1.67) nor among patients followed with a watch-and-wait approach (HR = 
1.30, 95% CI: 0.47, 3.63). 
The nested case-control analysis assessing statin use at any time during follow-up included 
896 cases (lymphoma-specific deaths) among NHL with 4,295 controls, and among CLL 235 
cases and 1,177 controls. For CLL patients with statin use there was a statistically significant 
reduced lymphoma-specific mortality (HR = 0.59, 95% CI: 0.41, 0.87), but there was no 
association in all NHL or other major subtypes. However, Burkitt lymphoma and FL patients 
under the watch-and-wait approach could not be assessed because of sparse numbers.  
When assessing all-cause mortality, in analyses of association with statin use before diagnosis 
there was a statistically significant reduction in all-cause mortality in T/NK-cell lymphoma 
patients (HR = 0.70, 95% CI: 0.50, 0.97) and in those with CLL (HR = 0.83, 95% CI: 0.69, 
0.99). In CLL patients, this association was seen in analyses of statin use after diagnosis as 
well (HR = 0.73, 95% CI: 0.59, 0.91). Statin use after diagnosis was also associated with an 
increased all-cause mortality in FL patients with a watch-and-wait approach. 
In neither study I or II did sensitivity analyses with additional adjustment for use of PPIs, 
SSRIs and number of non-primary outpatient doctors’ visits (included together in the 
sensitivity models) considerably change the results (in MM HR = 0.74 [95% CI: 0.61, 0.90] 
for statin use after diagnosis with additional adjustment vs HR = 0.73 [95% CI: 0.60, 0.89] in 
main analyses, and in NHL HR = 0.93 [95% CI: 0.77, 1.12] for both sensitivity and main 
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analyses , and in CLL HR = 0.77 [95% CI: 0.54, 1.10] with additional adjustment vs HR = 
0.79 [95% CI: 0.55, 1.12] in main analysis). 
In study II we also explored different exposure lags, 3 and 9 months respectively, which did 
not considerably change the results.  In further sensitivity analyses we required 2 
dispensations of statins per 6-month period before and after diagnosis respectively in order to 
be considered as a statin user. This logically resulted in slightly fewer statin users, but effect 
estimates remained similar.  
The majority of the patients in both study I and II used medium intensity statin therapy, at 
baseline 67% among both MM and lymphoma patients, compared to low intensity 29% in 
MM and 30% in lymphoma, and high intensity 4% in lymphoma and 3% in MM. In neither 
of the studies multivariable adjusted analyses showed any statistically significant evidence of 
a dose-response relationship with disease-specific mortality. As for all-cause mortality, in 
study II the trend test for intensity of statin treatment and all-cause mortality was significant 
for statin use after diagnosis of NHL (multivariable adjusted ptrend=0.001). 
We found no association between duration of statin use and disease-specific mortality for 
patients with MM, all NHL or CLL in trend tests, but CLL patients with statin use >2 years 
had a statistically significant improved lymphoma-specific survival (HR = 0.51, 95% CI: 
0.30, 0.86). 
The validation study of disease-specific mortality showed excellent PPV for both myeloma-
specific and lymphoma-specific mortality, 97% and 98% respectively, using the medical 
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Fig 5.1. Hazard Ratios (HR) and 95% confidence intervals (CI) for the association of statin 
use in periods before (A), after (B) and any time during follow-up (C) with disease-specific 
mortality for lymphoid neoplasms including multiple myeloma in Sweden 2007-2013  
 
Notes: HRs were calculated with Cox proportional hazards regression models in cohort analyses (A+B) and 
approximated by ORs in conditional logistic regression models (C) given that incidence density sampling was 
used when sampling the controls in the case-control-study 
Abbreviations: CI=Confidence Interval, NHL= non-Hodgkin lymphoma (except CLL), DLBCL= Diffuse Large B-
Cell Lymphoma, FL= Follicular lymphoma, w&w= followed with a watch-and-wait approach (no rituximab 
treatment), MCL= Mantle Cell Lymphoma, MZL= Marginal Zone Lymphoma, NK Cell= Natural Killer Cell, LPL= 
Lymphoplasmacytic Lymphoma, CLL= Chronic Lymphocytic Leukemia 
*Adjusted: Covariates adjusted for: Age category, sex, year of diagnosis, highest education level, concomitant 
medication (yes/no) for: diabetes, anticoagulants, diuretics, beta-blockers, ACE inhibitors, Calcium channel 
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5.2 MAIN RESULTS OF STUDY III 
We identified 78,233 women in NHS who met the inclusion criteria, 46% of whom used 
aspirin at baseline. During 1,776,841 person-years we confirmed 868 incident NHL 
diagnoses including 128 with DLBCL, 148 with FL, 251 with CLL/SLL and 28 with T-cell 
lymphoma.  
Overall, we observed no statistically significant associations of current aspirin use status (e.g., 
yes/no regular use) with risk of NHL overall or any of the subtypes. When categorizing 
aspirin use as cumulative average quantity of tablets/week, there was a statistically significant 
increased risk of FL for users of 5+ tablets/week, with a multivariable adjusted HR = 1.89 
(95% CI: 1.03, 3.48) and with a significant trend across increasing category of cumulative 
average quantity (p=0.04) (Table 5.2). We saw no clear trends for the other subtypes.  
In the analyses of duration of aspirin use, we did not observe any biologically plausible 
trends. Neither did we see any suggestion of confounding of the association of any aspect of 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3 MAIN RESULTS OF STUDY IV 
We identified 359 cases of incident immunocompetent PCNSL during the period. The overall 
incidence of PCNSL per 100,000 person-years was 0.26 (95% CI: 0.24, 0.29) and the average 
annual increase 4% (p=0.002). The increasing trend was primarily observed among elderly 
individuals (70+ years at diagnosis), in this group the average annual increase was 6% (95% 
CI: 1.02-1.10, p = 0.005) (Fig 5.2). This was consistent with a similar increasing incidence of 
brain tumors of any type primarily in the elderly.  
There were 265 (74%) deaths during follow- up, the majority during the first year after 
diagnosis (73%), giving a median all-cause survival of 7.6 months (range: 0- 14.9 years). The 
overall 1- and 5- year relative survival was 0.43 (95% CI: 0.38- 0.48) and 0.24 (95% CI: 
0.19- 0.29), respectively. 
There was no significant improvement in relative survival across the study period although, 
for patients diagnosed in the first calendar period (2000- 2002), the relative survival curve 
appeared to flatten out after approximately 6 years of follow- up, and the same was seen 
among fit patients (with ECOG 0 at diagnosis) where survival also plateaued 6 years after 
diagnosis. However, there was little support for statistical cure in the group of patients aged 
<59 years at diagnosis, although relative survival was highest in this group compared to in 
other groups. No significant difference in the excess mortality rate for PCNSL patients was 




























































































































In this thesis we build upon earlier studies of common medication use in relation to the risk 
and prognosis of lymphoid neoplasms, using Swedish population-based registers and detailed 
American cohort data. We also investigate the epidemiology of PCNSL in Sweden.  
We found that statin use after diagnosis is associated with improved disease-specific survival 
in patients with MM, whereas no such consistent association was seen for NHL or major 
NHL subtypes including CLL. We found no evidence of reduced survival in the subset of 
rituximab-treated FL patients versus FL patients managed with watch-and-wait. 
In analyses of aspirin use, we found no evidence of reduced incidence of NHL for aspirin 
users. Instead, when assessing subtypes separately, there was some evidence of increased risk 
of FL for higher quantity aspirin users.  
There was an increasing incidence of PCNSL in the elderly in Sweden, which we believe is 
due at least in part to increased diagnostics and reporting in that age group. There was no 
overall improvement in PCNSL survival during this period, despite the new treatments 
introduced. 
Although observational research inherently carries the risk of several types of biases, it can 
provide important information, and is an essential complement to RCTs. This is especially 
true for “old medications” like aspirin or statins in which pharmaceutical companies no 
longer make investments. It is also important for rare outcomes or for outcomes with long 
induction periods that are hard to capture within the time-frame of an RCT. There are several 
instances where observational studies have found clinically important associations that have 
later been confirmed in RCTs. Early examples include the strong negative association 
between aspirin and acute myocardial infarction (AMI) reported in in a 1974 study,116 as well 
as the strong negative association between intake of folic-acid in the first trimester of 
pregnancy and neural tube defects117 and the increased risk of thromboembolism in tamoxifen 
users.118 Examples from the NHS cohort include, as previously mentioned, a reduced risk of 
colorectal cancer in aspirin users, but also the first indication of an increased risk of venous 
thromboembolism among estrogen users, the latter subsequently reported in several other 
observational studies.119-123  
There are, of course, also examples in which the results of observational studies and RCTs 
have been conflicting,124 and we need to rigorously consider both our study design and 
potential alternative explanations for findings in observational studies. 
The demand for information about medication use and treatment outcomes in the real world 
is increasing. At the same time, the costs and time required for RCTs has increased, leading 
to fewer rather than more new drugs being approved (Fig 6.1). The information available in 
the Swedish population-based registers have a high coverage and quality, and can help fill 




Fig 6.1. The number of new drugs approved by US Food and Drug Administration (FDA) per 
billion US dollars (inflation-adjusted) spent on research and development has halved roughly 
every 9 years, a rate of decline that is fairly similar across recent decades. From Scannell J, 
Diagnosing the decline in pharmaceutical R&D efficiency, Nature Reviews Drug Discovery 
2012.125 
6.1 STUDY I AND II  
The association between statin use and improved myeloma-specific survival is intriguing. 
The consistency with the results of the only large study published so far32 and the biological 
rationale with a potential mechanism of action similar to the well proven MM treatment with 
bisphosphonates add to the plausibility. However, with this study we cannot say whether the 
association is truly causative.  
A strength of the studies is that we were able to evaluate the intensity of statin treatment in 
the most evidence-based way, using the ACC/AHA guidelines. We wanted to use an intensity 
scale that aligns with the biological response to statin dose in terms of cholesterol reduction 
in the blood. A disadvantage with this method was somewhat reduced statistical power, given 
that very few subjects were in the highest intensity category (3 and 4% respectively). 
Some authors stress that when evaluating studies of associations between statin use and 
cancer mortality it is important to compare the magnitude of the inverse association to the 
results from studies of cardiovascular mortality prevention.126 They argue that a stronger 
beneficial effect in cancer prevention as compared to in cardiovascular prevention is not 
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plausible. A meta-analysis of RCTs assessing statin use in adults at increased cardiovascular 
risk but without prior cardiovascular events, reported the RR (95% CI) for all-cause mortality 
to be 0.86 after 1-6 years (95% CI, 0.80, 0.93).127 An observational study using American 
claims data to quantify the statin effect on AMI occurrence, used a 52-variable propensity 
score to match the statin-users and non-users, and found a 31 % risk reduction for AMI 
events.128 Our results are within this spectrum, with lower point estimates for the association 
of statin use 6 months after diagnosis with myeloma-specific mortality (HR = 0.73, 95% CI: 
0.60, 0.89) than with all-cause mortality (HR = 0.81, 95% CI: 0.69, 0.9). 
Several biases need to be considered when interpreting these results. Ideally, in order to 
mitigate confounding by indication and healthy user bias, and seeking to approximate the 
design of a RCT in an observational study, we should have used an active comparator, new 
user design (ACNU).129-131 Using an active comparator, the medication of interest is 
compared with another drug commonly used for the same indication, rather than with no 
treatment at all. However, given that virtually all lipid-lowering medications prescribed are 
statins, it is difficult to find an active comparator to statins. 
With a new user design, only new users of the medication are included in the study. 
However, we had very few new users in our material, among MM patients only 77 (2.26%) 
were probable new users after diagnosis (i.e. had no statin dispensations during the 6 months 
before diagnosis but had statin dispensations during the 6-month period after diagnosis), and 
in the studied NHL/CLL cohort 295 (2.28%) were probable new users. A new user design 
would thus not have been feasible for the statin studies. 
Not being able to use the ACNU design to address these possible biases, let us consider in 
what way our analyses would be distorted by them if present. Residual confounding by 
indication and healthy user bias typically would have affected our results in opposite ways. 
Whereas confounding by indication tends to lead to estimates showing increased risk (the 
medication under study thus seeming more harmful given that only those who are sick get the 
medication prescribed), the healthy user bias introduces a bias towards a more “protective” 
effect of the medication under study (given that the health-aware or healthy subjects are more 
prone to start using the medication as well as to adhere to it). 
We aimed to assess possible healthy user bias in sensitivity analyses by adjusting for use of 
PPIs and SSRIs and number of non-primary care doctor outpatient visits, and we did not find 
evidence of a pronounced healthy user bias. Given that healthcare in Sweden is tax funded 
with a very low out-of-pocket cost, statins are accessible for all socioeconomic groups, and in 
our studies we did not find higher levels of attained education among statin users compared to 
non-users. In all, healthy-user bias does not appear to be the major explanation of our 
findings. As for confounding by indication, we should suspect some remaining confounding 
by indication by cardiovascular disease in our studies, despite having adjusted for use of 
medications for cardiovascular disease. If so however, this would likely distort our results 
towards a more harmful effect of statins. 
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We made efforts to avoid immortal time bias by using a landmark analysis excluding the 
period of statin exposure assessment in the cohort studies. We also excluded the period of 
exposure assessment before start of follow-up in the nested case control studies. The potential 
bias introduced by reverse causation, such as when cancer patients stop prophylactic 
medications near the end of life or initiate medication use to address symptoms of subclinical 
disease, is more complex. A Swedish study by Morin et al reported that patients with solid 
cancers stopped taking statins the month before death (as compared to their use 12 months 
before death) more frequently than, for example antihypertensive medications (4.7% absolute 
change for statins compared to 0.3% for medications used to treat hypertension).105 However, 
the authors chose not to include hematological malignancies in the study because they 
reasoned that the prognosis of hematological malignancies is often unclear until late in the 
disease, and use patterns therefore less predictable. The potential bias introduced by reverse 
causation here would create an inverse association in which statins would falsely seem to 
improve survival. This potential bias is hard to account for other than by restricting the period 
of exposure assessment to avoid assessment of statin use during the last period of life or, as in 
the aspirin analyses of study III, implementing exposure lags that account for the potential 
influence of subclinical disease on use habits. 
Although we used the same methodology for all lymphoid neoplasms in the statin studies, we 
found improved disease-specific survival in patients with MM but not in those with NHL. For 
those differences to be explained by reverse causation, MM patients would have had to stop 
their prophylactic medications longer before death than NHL patients. In order to explore 
this, we performed analyses with longer exposure lags in the MM cohort. These analyses 
have limited power, given that fewer patients survived long enough to remain in the analysis. 
Also, these studies likely carry a larger degree of statin exposure misclassification given that 
more patients change exposure status with time. However, in these studies we observed only 
a loss of precision rather than modifications of the associations of statin use and MM 
survival, arguing against this as a major explanation of our findings. 
In NHL and CLL, there was no consistent evidence of association of statin use with reduced 
lymphoma-specific mortality in any subtype. The observed reduced lymphoma-specific 
mortality in Burkitt lymphoma is interesting, but could only be assessed in one time-interval 
and was based on very few patients, and could thus also have arisen due to chance. In patients 
with CLL, there was improved lymphoma-specific survival only for statin use at any time 
during follow-up, and for >2 years duration of statin use. Given that all-cause mortality was 
significantly improved for CLL patients with statin use in both of the time intervals 
investigated, the results for lymphoma-specific mortality could be driven by cardiovascular 
prevention. Another possibility however, considering the significant results for the longer 
duration, is that our follow-up time was too short to capture a possible longer-term reduction 
in mortality among statin users. Cancer progression is often slow, even more so for indolent 
lymphoma and CLL. As a comparison, the inverse association of aspirin with risk of 
colorectal cancer was only seen after 10 or more years of aspirin use in an RCT in the 
Women’ Health Study.132 
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6.2 STUDY III 
In study III, the finding of an increased risk for FL for users of high quantities of aspirin, was 
consistent with the only published large prospective study to date with detailed subtype data 
including analyses of FL, adding plausibility to our finding.64 Despite the large cohort size 
however, we had a relatively small number of FL patients to analyze, illustrating that even 
larger sample sizes are needed to investigate this association further. In the analyses of 
duration of aspirin use, we did not observe any biologically plausible trends. Although there 
is no known mechanism for this putative association, FL etiology differs from that of other 
lymphomas in several aspects worth noting. It affects men and women equally133,134, and 
there is no evidence of risk increase with immunosuppression135. Whether its risk may be 
increased by aspirin use warrants further investigation. 
A limitation of the study is that we were not able to assess low (baby) and high (adult) 
strength aspirin use separately. However, detailed data about other aspects of the aspirin 
exposure such as quantity and duration of use was available for more than 25 years of follow-
up. Also, our study is conservative in that we excluded patients with RA in order to avoid 
confounding. Also, in order to attenuate reverse causation by aspirin use for symptoms of 
subclinical disease in this indolent and slow growing lymphoma, we used a 4-year exposure 
lag in the analyses.  
Regarding NHL overall, we did not find any associations with any aspect of aspirin use. In 
all, together with the results from previously published cohort studies, it does not seem likely 
that aspirin has a role in the prevention of lymphoma similar to what has been shown in 
colorectal cancer. The fact that we, equivalent with the previous large prospective study 
described above, found a possible risk increase for the indolent lymphoma subtype FL cannot 
outweigh the benefits aspirin adds in cardiovascular prevention, so this finding has no 
immediate clinical implications. However, if this finding is confirmed in larger studies, an 
increased awareness for longtime aspirin users could be warranted. 
6.3 STUDY IV 
In study IV, the increasing incidence of PCNSL in the elderly is consistent with studies 
based on SEER data (period of diagnosis 1980–2011), that also showed a continuously 
increasing incidence for the oldest patients.9,14 In our study, this corresponded with an 
increasing trend in brain tumors of all kinds in Sweden in the same age group. This indicates 
that an increasing tendency to diagnose and report CNS tumors in the elderly may at least in 
part explain the findings. During this period, the possibilities to perform computer 
tomography (CT) and magnetic resonance imaging (MRI) scans, and also to perform some 
invasive diagnostic procedures have increased, making it accessible even for the elderly.  In 
the SEER study, that unlike our study also included HIV positive and other 
immunocompromised patients, another possible explanation is that the increase could in part 
be due to the elderly population receiving more immunosuppressive treatments after 
transplantations and as treatments for autoimmune diseases. In our study, although we 
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excluded HIV positive cases and recipients of organ transplants, we were not able to exclude 
patients with other immunocompromizing conditions. More intensive immunosuppressing 
regimens used to treat i.e. rheumatoid arthritis and other autoimmune diseases could possibly 
also contribute to the increasing PCNSL incidence, although to a very minor degree. 
Regarding survival, we found the overall 1-  and 5- year relative survival to be  0.43 (95% 
CI: 0.38- 0.48) and 0.24 (95% CI: 0.19- 0.29), respectively, and the median all- cause 
survival was 7.6 months (range: 0- 14.9 years). This is lower than the SEER study, that for 
subjects diagnosed between 2000 and 2008, reported the overall 1- and 5-year relative 
survival estimates to be 51.4% and 31.2%, respectively, with a median relative survival of 
14 months.9 This is surprising, given that the SEER study also included HIV positive cases. 
An earlier American study that compared HIV positive cases of PCNSL from presumably 
HIV negative cases found a considerable difference in prognosis, with a median overall 
survival of only 2 months for HIV positive patients vs 12 months in the HIV negative136. 
To conclude, although our study disappointingly did now show evidence of improved 
survival, our study period included many patients from the period before modern HD-MTX-
based regimens, and a more recent study period as well as a longer follow-up is warranted to 
evaluate survival with modern regimens. Also, the possible increase in incidence in the 






Statin use is associated with improved myeloma-specific survival. Whether this reflects a 
causal association requires assessment in a RCT setting. 
Statin use is not associated with lymphoma-specific survival in NHL patients overall. 
Possible long-term mortality reductions in CLL patients or those with less common subtypes 
warrants further investigation in larger studies with longer follow-up. We found no evidence 
of interaction between statin use and rituximab treatment in patients with FL, suggesting that 
statins can be continued safely during FL treatment. 
Study III 
Aspirin use was not associated with risk of NHL overall, but a possible increase in risk of FL 
for users of larger quantities of aspirin warrants further study in larger populations. 
Study IV 
The incidence of PCNSL in the elderly is increasing in Sweden, but this may at least in part 
be due to increased diagnostics and reporting. While we observed no improvement in PCNSL 
survival during the study period, studies with longer follow-up are needed to evaluate the new 




8 POINTS OF PERSPECTIVE 
Lymphoid neoplasms are relatively rare, and despite the fact that the studies in this thesis are 
all among the larger of their kinds, the statistical power for subtype-specific analyses is 
limited. Several questions that remain after this thesis would benefit from being tested in even 
larger study populations. A tempting next step would be to pool data from the registers of the 
other Nordic countries that also have excellent coverage by population-based registers 
organized in similar ways as the Swedish registers. This would provide better power, for 
example for studies of intensity of statin use, for which the limited number of high-intensity 
users hindered our detection of significant associations in dose-response tests. Pooling Nordic 
data would also be useful for subtype-specific analyses, for example in the Burkitt subtype. 
Furthermore, a longer follow-up would be desirable, especially for the indolent subtypes such 
as CLL.  
To build further on our aspirin study, we plan to add the men from a similarly designed male 
cohort, the Health Professionals Follow-up Study (HPFS). We plan to pool our NHS data 
with the data from approximately 37,750 men with available comparable aspirin use 
information, adding an expected additional 450 cases of NHL during the follow-up period. In 
the future, aspirin use and NHL risk could also be evaluated in Nordic register data. 
As for the PCNSL study, an updated study assessing the medical records of the PCNSL 
patients treated at the Karolinska hospital is ongoing. A complementary analysis in pooled 
data from the Nordic countries with added treatment information from the lymphoma 
registers of the respective countries would be highly informative, in particular to assess a 
larger study population treated with HD-MTX-based regimens. Also, a longer follow-up 
would enable us to assess long-term effects of these new treatments in a population-based 
setting. Furthermore, pooled data from the Nordic countries would enable us to assess 
treatment outcomes with the tyrosine kinase inhibitor ibrutinib in a population-based setting. 
This new treatment, taken as a pill, has shown promising results in small studies, but larger 
studies are still lacking. 
A challenge with research in the SLR has been incomplete data for certain variables in the 
earlier years, such as treatment information. The completeness of this information is 
improving, which is reassuring and essential for register-based research on chemotherapy 
treatments and other treatments that are not covered by the drug register. However, many of 
the new medications are pills taken at home, which are thus possible to capture through the 
drug register.  
Further possibilities with pooled Nordic data would be to assess combinations of treatments, 
which is often used in the hematology/oncology setting. The promising results reported for 
combinations of venetoclax and statins in NHL patients137 and for, or statins acting as 
sensitization for anthracycline treatment in acute myeloid leukemia138 are examples of this.  
In order to further evaluate possible reverse causation in studies I and II of this thesis, patterns 
of deprescription of medications towards the end of life in the Swedish population ideally 
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should be better characterized. Future studies investigating these patterns are thus warranted. 
This would help disentangle mechanisms of possible reverse causation not only in the studies 
of this thesis, but of future studies of other medications and cancer survival as well. 
As a next step, register-based controlled trials similar to those performed initially to evaluate 
cardiovascular interventions139,140 would be ideal in the hematology/oncology setting, and an 
optimal approach for further confirmation of many of the results of this thesis. A possible 
RCT adding statin to any other physician’s choice of MM treatment at time of MM diagnosis 
could be an example.  
 
Fig 8.1 From Lee M et al: Innovation in Regulatory Science Is Meeting Evolution of Clinical 
Evidence Generation, Clinical Pharmacology and Therapeutics, 2019141 
To conclude, considering the increasing challenges in terms of time and costs required for 
RCTs, the relative rarity of lymphoid neoplasms and the explosion of new treatment options 
available or in development for many conditions in the hematology/oncology setting141 (Fig 
8.1), the need to evaluate their benefits in a real-world setting is increasing. This is also 
important for intensive treatments like the HD-MTX regimens in PCNSL. We have a lot to 
gain by understanding the pitfalls and possibilities of our registers and available real-world 
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